Brad Enerson

Statistics

Publications

Citations

103

H-Index

Active since

2024

Affiliations

Woomera Therapeutics(Current)

Brad Enerson is an author at Woomera Therapeutics specializing in cytokine receptor signaling, b-cell malignancy therapy, and anti-inflammatory pharmacology.

Publications per year

2024–2024

Publications

Discovery of KT-474─a Potent, Selective, and Orally Bioavailable IRAK4 Degrader for the Treatment of Autoimmune Diseases

Xiaozhang Zheng, Nan Ji, Veronica A. Campbell et al. · Journal of Medicinal Chemistry · 2024 · 64 citations · Full text

Life Sciences, Medicinal Chemistry, Pharmacology +15

Discovery of KT-413, a Targeted Protein Degrader of IRAK4 and IMiD Substrates Targeting MYD88 Mutant Diffuse Large B-Cell Lymphoma

Matthew M. Weiss, Xiaozhang Zheng, Nan Ji et al. · Journal of Medicinal Chemistry · 2024 · 39 citations · Full text

Medicine, Molecular Biology, Oncology +15

1–2 of 2